Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Follow-Up Questions
What is Alkermes Plc (ALKS)'s P/E Ratio?
The P/E ratio of Alkermes Plc is 14.4135
Who is the CEO of Alkermes Plc?
Mr. Richard Pops is the Chairman of the Board of Alkermes Plc, joining the firm since 2011.
What is the price performance of ALKS stock?
The current price of ALKS is $29.85, it has increased 0.16% in the last trading day.
What are the primary business themes or industries for Alkermes Plc?
Alkermes Plc belongs to Biotechnology industry and the sector is Health Care
What is Alkermes Plc market cap?
Alkermes Plc's current market cap is $4.9B
Is Alkermes Plc a buy, sell, or hold?
According to wall street analysts, 19 analysts have made analyst ratings for Alkermes Plc, including 5 strong buy, 12 buy, 6 hold, 0 sell, and 5 strong sell
